Fumihiro Kawakita Selected Research

Glutamates

3/2022

Neuroelectric Mechanisms of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fumihiro Kawakita Research Topics

Disease

26	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2022 - 01/2015
11	Brain Injuries (Brain Injury) 01/2022 - 01/2016
8	Brain Edema (Cerebral Edema) 01/2020 - 01/2016
6	Intracranial Vasospasm 01/2020 - 01/2015
5	Brain Ischemia (Cerebral Ischemia) 10/2019 - 01/2011
3	Hydrocephalus (Hydrocephaly) 10/2021 - 08/2017
3	Cerebral Infarction 01/2020 - 01/2018
3	Herpes Zoster 02/2019 - 06/2016
2	Ischemia 03/2022 - 02/2021
2	Stroke (Strokes) 01/2022 - 12/2019
2	Wounds and Injuries (Trauma) 10/2021 - 02/2015
2	Neuroinflammatory Diseases 01/2020 - 11/2018
2	Muscle Spasticity (Spastic) 01/2020 - 10/2017
2	Neoplasms (Cancer) 07/2019 - 04/2018
1	Seizures (Absence Seizure) 03/2022
1	Edema (Dropsy) 01/2020
1	Rupture 01/2020
1	Intracranial Aneurysm (Cerebral Aneurysm) 01/2020
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020
1	Aneurysm (Aneurysms) 10/2019
1	Pathologic Constriction (Stenosis) 10/2018
1	Unconsciousness (Loss of Consciousness) 07/2018
1	Meningioma (Meningiomas) 04/2018
1	Infarction (Infarctions) 01/2018
1	Inflammation (Inflammations) 01/2018
1	Pain (Aches) 12/2016
1	Hypesthesia (Numbness) 12/2016
1	Hyperplasia 02/2015
1	Ischemic Stroke 01/2011
1	Transient Ischemic Attack 01/2011

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2015
12	TenascinIBA 01/2020 - 01/2015
6	PeriostinIBA 01/2021 - 01/2017
5	Toll-Like Receptor 4IBA 01/2020 - 10/2017
4	OsteopontinIBA 10/2021 - 01/2016
3	Glutamic Acid (Glutamate)FDA Link 03/2022 - 02/2021
3	Galectin 3 (LGALS3)IBA 10/2019 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 10/2019 - 01/2018
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2019 - 01/2016
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 07/2019
2	Cilostazol (Pletal)FDA LinkGeneric 01/2020 - 08/2017
2	LigandsIBA 01/2020 - 01/2020
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020 - 08/2017
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 02/2019 - 01/2017
2	Coloring Agents (Dyes)IBA 04/2018 - 06/2016
1	GlutamatesIBA 03/2022
1	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2022
1	PropionatesIBA 01/2022
1	Clarithromycin (Biaxin)FDA LinkGeneric 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2020
1	Mitogen-Activated Protein KinasesIBA 01/2020
1	CaspasesIBA 01/2020
1	Heme (Haem)IBA 01/2020
1	NF-kappa B (NF-kB)IBA 01/2020
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 07/2019
1	Protein Isoforms (Isoforms)IBA 02/2019
1	Tight Junction ProteinsIBA 02/2019
1	IAXO-102IBA 02/2019
1	JNK Mitogen-Activated Protein KinasesIBA 02/2019
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 11/2018
1	citrus pectinIBA 11/2018
1	Neuroprotective AgentsIBA 11/2018
1	Cyclooxygenase 1IBA 10/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	Phosphates (Orthophosphate)IBA 06/2016
1	Evans Blue (Blue, Evans)FDA Link 06/2016
1	Matrix Metalloproteinases (MMPs)IBA 06/2016
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2016
1	Immunoglobulins (Immunoglobulin)IBA 01/2016
1	Extracellular Matrix ProteinsIBA 01/2016
1	Angiotensin II Type 1 Receptor BlockersIBA 02/2015
1	CholesterolIBA 02/2015
1	p38 Mitogen-Activated Protein KinasesIBA 01/2015

Therapy/Procedure

3	Therapeutics 10/2018 - 06/2016
1	Molecular Targeted Therapy 11/2018
1	Decompression 12/2016
1	Stents 02/2015
1	Oral Administration 02/2015
1	Catheters 02/2015
1	Cerebral Revascularization 01/2011